New Treatment Approaches Emerging for Cannabinoid Hyperemesis Syndrome
A clinical review outlines updated CHS treatment strategies including dopamine antagonists for acute episodes and addressing underlying mental health conditions for long-term management.
Quick Facts
What This Study Found
Beyond the traditional advice of complete THC cessation, current evidence supports using dopamine antagonists in acute CHS episodes, along with IV fluids, capsaicin cream, and standard antiemetics. Treating co-occurring anxiety, depression, and substance use disorder is now seen as critical for sustained recovery.
Key Numbers
CHS first identified in 2004. Only known cure remains complete THC cessation. Dopamine antagonists identified as useful acute-phase treatment.
How They Did This
Clinical review synthesizing current evidence on CHS pathogenesis, diagnosis, and management in both acute and chronic phases.
Why This Research Matters
CHS prevalence is rising with legalization, and many clinicians still struggle with diagnosis and management. Updated treatment recommendations that go beyond "just stop using" could improve patient outcomes.
The Bigger Picture
CHS sits at the intersection of cannabis use, mental health, and emergency medicine. The shift toward treating underlying conditions rather than just symptoms represents a more holistic approach to a syndrome that frequently leads to repeated ER visits.
What This Study Doesn't Tell Us
Evidence base for CHS treatment remains limited. No large randomized trials guide management. Pathogenesis still poorly understood.
Questions This Raises
- ?Which dopamine antagonist is most effective for CHS?
- ?Can harm reduction approaches work, or is complete cessation truly the only cure?
- ?What role does cannabis potency play in CHS development?
Trust & Context
- Key Stat:
- Dopamine antagonists and treating co-occurring mental health conditions now part of CHS management
- Evidence Grade:
- Expert clinical review synthesizing available evidence, but underlying studies are mostly case series and observational.
- Study Age:
- 2025 review incorporating the most current CHS management evidence.
- Original Title:
- Current recommendations in the diagnosis and management of cannabinoid hyperemesis syndrome.
- Published In:
- Current opinion in pediatrics, 37(3), 240-243 (2025)
- Authors:
- Meyer, Joshua, Burns, Michele M(3)
- Database ID:
- RTHC-07127
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How is cannabinoid hyperemesis syndrome treated?
Acute episodes are managed with IV fluids, dopamine antagonists, capsaicin cream, and antiemetics. Long-term management requires THC cessation plus treatment of underlying conditions like anxiety, depression, or substance use disorder.
Is there a cure for CHS besides quitting cannabis?
Complete cessation of THC-containing products remains the only known definitive treatment. However, new approaches focusing on co-occurring mental health conditions may help people achieve and maintain abstinence.
Read More on RethinkTHC
- 420-sober-survival-guide
- CBT-cannabis-recovery
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-relapse-cycle-pattern
- cannabis-use-disorder-test
- cold-turkey-vs-taper-quit-weed
- cross-addiction-quit-weed-start-drinking
- dating-sober-after-quitting-weed
- exercise-quitting-weed-anxiety-brain
- grieving-quitting-weed-loss
- help-someone-quit-weed
- how-to-quit-weed
- is-weed-addictive
- is-weed-addictive-science
- journaling-weed-withdrawal
- marijuana-anonymous-SMART-recovery-compare
- meditation-mindfulness-weed-withdrawal
- partner-still-smokes-weed
- partner-still-smokes-weed-quitting
- pink-cloud-sobriety-cannabis
- quit-weed-cold-turkey
- quit-weed-or-cut-back-which-is-better
- quit-weed-regret-went-back
- quitting-weed-20s
- quitting-weed-30s
- quitting-weed-after-years
- quitting-weed-and-alcohol
- quitting-weed-during-crisis-divorce-job-loss
- quitting-weed-exercise
- quitting-weed-grief-loss-coping
- quitting-weed-legal-state
- quitting-weed-success-stories
- quitting-weed-triggers-environment
- rehab-for-weed-addiction-necessary
- relapsed-smoking-weed-what-to-do
- relapsed-weed
- should-i-quit-weed
- signs-of-cannabis-use-disorder
- sober-music-festival-concert-without-weed
- supplements-weed-withdrawal
- telling-friends-quitting-weed
- weed-relapse-prevention-plan
- weed-relapse-why-it-happens
- weed-ritual-replacement
- weed-ruined-relationships
- weed-social-media-triggers-quit
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-07127APA
Meyer, Joshua; Burns, Michele M. (2025). Current recommendations in the diagnosis and management of cannabinoid hyperemesis syndrome.. Current opinion in pediatrics, 37(3), 240-243. https://doi.org/10.1097/MOP.0000000000001464
MLA
Meyer, Joshua, et al. "Current recommendations in the diagnosis and management of cannabinoid hyperemesis syndrome.." Current opinion in pediatrics, 2025. https://doi.org/10.1097/MOP.0000000000001464
RethinkTHC
RethinkTHC Research Database. "Current recommendations in the diagnosis and management of c..." RTHC-07127. Retrieved from https://rethinkthc.com/research/meyer-2025-current-recommendations-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.